Physical Frailty and Use of Guideline‐Recommended Drugs in Patients With Heart Failure and Reduced Ejection Fraction
Journal of the American Heart Association · 20.06.2023 · 12 (12)
DOI: 10.1161/jaha.122.026844 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of the American Heart Association, erschienen am 20.06.2023. Verfasst von Toru Kondo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology Nagoya University Graduate School of Medicine Nagoya Japan. Hauptthemen laut MEDLINE: Frailty, Heart Failure. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Herzinsuffizienz, Gerontologische Pflege
Abstract (Originalsprache)
BACKGROUND Guideline‐recommended therapies that improve prognosis remain underused in clinical practice. Physical frailty may lead to underprescription of life‐saving therapy. We aimed to investigate the association between physical frailty and the use of evidence‐based pharmacological therapy for heart failure with reduced ejection fraction and the impact of this on prognosis. METHODS AND RESULTS The FLAGSHIP (Multicentre Prospective Cohort Study to Develop Frailty‐Based Prognostic Criteria for Heart Failure Patients) included patients hospitalized for acute heart failure, and data on physical frailty were collected prospectively. We analyzed 1041 patients with heart failure with reduced ejection fraction (aged 70 years; 73% male) and divided them by physical frailty categories using grip strength, walking speed, Self‐Efficacy for Walking–7 score, and Performance Measures for Activities of Daily Living–8 score: categories I (n=371; least frail), II (n=275), III (n=224), and IV (n=171). Overall prescription rates of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, β‐blockers, and mineralocorticoid receptor antagonists were 69.7%, 87.8%, and 51.9%, respectively. The proportion of patients receiving all 3 drugs decreased as physical frailty increased (in category I patients, 40.2%; IV patients, 23.4%; P for trend
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology Nagoya University Graduate School of Medicine Nagoya Japan.
- British Heart Foundation Cardiovascular Research Centre University of Glasgow UK.
- Department of Integrated Health Sciences Nagoya University Graduate School of Medicine Nagoya Japan.
- Department of Rehabilitation Nagoya University Hospital Nagoya Japan.
- Department of Cardiology Fujita Health University Toyoake Japan.
ORCID-Profile: Toru Kondo, Takuji Adachi, Takahiro Okumura, Hideo Izawa, Toyoaki Murohara, John J V McMurray
Zitieren
APA
Kondo, T., Adachi, T., Kobayashi, K., Okumura, T., Izawa, H., Murohara, T., McMurray, J. J. V., & Yamada, S. (2023). Physical Frailty and Use of Guideline‐Recommended Drugs in Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American Heart Association, 12(12). https://doi.org/10.1161/jaha.122.026844
Vancouver
Kondo T, Adachi T, Kobayashi K, Okumura T, Izawa H, Murohara T, et al. Physical Frailty and Use of Guideline‐Recommended Drugs in Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American Heart Association. 2023;12(12). doi:10.1161/jaha.122.026844
BibTeX
@article{Kondo2023,
author = {Kondo, Toru and Adachi, Takuji and Kobayashi, Kiyonori and Okumura, Takahiro and Izawa, Hideo and Murohara, Toyoaki and McMurray, John J V and Yamada, Sumio},
title = {Physical Frailty and Use of Guideline‐Recommended Drugs in Patients With Heart Failure and Reduced Ejection Fraction},
journal = {Journal of the American Heart Association},
year = {2023},
volume = {12},
number = {12},
doi = {10.1161/jaha.122.026844}
}
EUVIMED